BRG1 and BRM Inhibitor Compounds for BAF Complex Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with alterations in the BRG1 and BRM proteins, such as cancer, lack effective compounds that can modulate the BAF complex to inhibit BRG1 and BRM activity.
Innovation Solution
Development of compounds with specific structures that can modulate the BAF complex, including BRG1 and BRM, to treat disorders by inhibiting their activity, either alone or in combination with other pharmaceutically active agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders associated with BRG1 and BRM alterations, then treatment options are available, but they lack effectiveness in modulating BAF complex to inhibit BRG1 and BRM activity
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (Formula I and Formula II) that target the ATPase domain of BRG1 and BRM proteins. These compounds alter the biochemical parameters of the BAF complex by inhibiting ATP hydrolysis, thereby changing the functional state of the chromatin remodeling complex to achieve therapeutic effects in cancer treatment
2Reliability
If compounds are developed to inhibit BRG1 and BRM activity, then therapeutic benefits are achieved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibition strategy into two distinct compound types: Formula I compounds that primarily inhibit BRG1, and Formula II compounds that primarily inhibit BRM. This segmentation allows for targeted inhibition of specific BAF complex subunits, providing therapeutic benefits while maintaining manageable structural complexity through modular design approaches
Solution Approach 2:
The patent applies local quality by designing compounds with specific structural features at particular positions (R1, R2, R3, R4, R5 substituents) to achieve selective inhibition. The local structural modifications at the ATPase binding interface enable precise targeting of BRG1 or BRM while maintaining overall compound manageability and facilitating structure-activity relationship optimization
Data Source
AI summary
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.